Your browser is no longer supported. Please, upgrade your browser.
VKTX Viking Therapeutics, Inc. daily Stock Chart
Viking Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own2.50% Shs Outstand72.36M Perf Week-0.44%
Market Cap502.45M Forward P/E- EPS next Y-0.83 Insider Trans-0.70% Shs Float63.20M Perf Month-5.52%
Income-30.50M PEG- EPS next Q-0.14 Inst Own55.90% Short Float18.85% Perf Quarter23.65%
Sales- P/S- EPS this Y6.50% Inst Trans0.36% Short Ratio7.24 Perf Half Y-6.16%
Book/sh3.71 P/B1.85 EPS next Y-36.10% ROA-10.70% Target Price- Perf Year-16.87%
Cash/sh3.67 P/C1.87 EPS next 5Y40.00% ROE-10.90% 52W Range3.26 - 8.87 Perf YTD-14.59%
Dividend- P/FCF- EPS past 5Y32.40% ROI- 52W High-22.77% Beta2.08
Dividend %- Quick Ratio32.40 Sales past 5Y- Gross Margin- 52W Low110.12% ATR0.37
Employees16 Current Ratio32.40 Sales Q/Q- Oper. Margin- RSI (14)44.63 Volatility3.97% 5.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-95.10% Profit Margin- Rel Volume0.70 Prev Close6.71
ShortableYes LT Debt/Eq0.00 EarningsApr 30 AMC Payout- Avg Volume1.64M Price6.85
Recom1.60 SMA20-5.77% SMA50-4.70% SMA2002.14% Volume1,149,968 Change2.09%
Jun-05-20Initiated BMO Capital Markets Outperform $14
May-05-20Initiated Chardan Capital Markets Buy $15
May-01-20Initiated BTIG Research Buy $9
Jul-16-19Initiated Oppenheimer Outperform $12
Jun-25-19Initiated Stifel Buy
Mar-29-19Upgrade SVB Leerink Mkt Perform → Outperform $10 → $21
Mar-14-19Reiterated Maxim Group Buy $28 → $20
Feb-22-19Initiated SVB Leerink Mkt Perform
Dec-12-18Initiated B. Riley FBR Buy $16
Nov-19-18Upgrade Raymond James Outperform → Strong Buy
Sep-18-18Reiterated Raymond James Outperform $15 → $43
Sep-18-18Reiterated Maxim Group Buy $14 → $28
Sep-18-18Reiterated H.C. Wainwright Buy $15 → $28
Jul-20-18Initiated SunTrust Buy $14
Jun-28-18Initiated Raymond James Outperform
Jun-01-18Reiterated Laidlaw Buy $10 → $15
May-31-18Reiterated Maxim Group Buy $8 → $14
Mar-26-18Resumed H.C. Wainwright Buy $11
Nov-28-17Reiterated Maxim Group Buy $5 → $8
Nov-21-17Initiated ROTH Capital Buy
Jun-29-20 01:32PM  
Jun-24-20 01:07PM  
Jun-15-20 05:19PM  
Jun-05-20 11:17AM  
May-27-20 07:30AM  
May-19-20 04:08PM  
May-12-20 05:00PM  
May-05-20 06:00AM  
May-04-20 12:24PM  
May-01-20 04:01PM  
Apr-28-20 07:30AM  
Apr-23-20 07:30AM  
Apr-07-20 07:30AM  
Mar-24-20 04:23PM  
Mar-23-20 08:32AM  
Feb-28-20 08:35AM  
Feb-27-20 05:45AM  
Feb-26-20 04:15PM  
Feb-24-20 07:30AM  
Feb-19-20 07:30AM  
Feb-05-20 04:11PM  
Jan-06-20 07:30AM  
Dec-14-19 09:44PM  
Dec-06-19 08:00AM  
Nov-21-19 06:50AM  
Nov-19-19 07:05AM  
Nov-15-19 12:27AM  
Nov-12-19 07:30AM  
Nov-09-19 03:53PM  
Nov-06-19 08:30AM  
Nov-05-19 05:09PM  
Oct-31-19 07:30AM  
Sep-25-19 07:30AM  
Sep-23-19 02:37PM  
Sep-09-19 10:00AM  
Aug-28-19 07:30AM  
Aug-13-19 07:00AM  
Aug-11-19 09:15AM  
Aug-08-19 01:31AM  
Aug-06-19 01:02AM  
Aug-05-19 04:42PM  
Aug-02-19 11:30AM  
Aug-01-19 04:05PM  
Jul-31-19 02:06PM  
Jul-25-19 04:05PM  
Jul-02-19 04:05PM  
Jun-20-19 02:15PM  
May-31-19 02:22PM  
May-28-19 07:30AM  
May-17-19 06:00AM  
May-14-19 11:06AM  
May-09-19 11:06AM  
May-08-19 12:03AM  
May-07-19 06:00AM  
May-03-19 03:00PM  
May-02-19 09:10PM  
Apr-30-19 07:30AM  
Apr-27-19 08:16AM  
Apr-25-19 07:30AM  
Apr-12-19 09:45AM  
Apr-11-19 08:52AM  
Apr-08-19 05:00PM  
Apr-06-19 08:03AM  
Apr-04-19 07:30AM  
Mar-31-19 09:00AM  
Mar-29-19 04:31PM  
Mar-28-19 07:30AM  
Mar-22-19 11:39AM  
Mar-19-19 01:56AM  
Mar-14-19 04:20PM  
Mar-13-19 04:05PM  
Mar-12-19 06:00AM  
Mar-06-19 07:30AM  
Feb-27-19 01:25PM  
Feb-26-19 07:30AM  
Feb-25-19 07:40AM  
Feb-21-19 08:00AM  
Feb-19-19 09:35AM  
Feb-17-19 08:20AM  
Feb-14-19 10:08AM  
Feb-12-19 04:20PM  
Feb-07-19 09:57PM  
Jan-23-19 03:10PM  
Jan-17-19 01:40PM  
Jan-16-19 04:18PM  
Jan-13-19 09:00AM  
Jan-12-19 06:00PM  
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WDirectorJun 30Sale7.3513,00095,55026,250Jun 30 05:54 PM